Retatrutide is an investigational compound that is not registered by SAHPRA. This page looks at the seller, not the product, and is not medical advice.

Seller review · Ranked 9 of 25

ReGen-X review

37

Our verdict

Clear about delivery costs and reachable by phone. It says every batch is independently tested, but we could not find a single report.

What we liked

  • Clear delivery prices and a low free-delivery threshold
  • Reachable by phone and WhatsApp
  • Card payments through PayFast

What gave us pause

  • Batch testing claimed with no reports
  • Two of three sizes out of stock or on backorder
  • No reviews yet

How the score breaks down

Six criteria, 100 points in total. See all 25 sellers or read how we rate.

  1. Lab reports

    8 / 30

    Says each batch is independently tested. No reports found.

  2. Customer reviews

    0 / 20

    A Google listing exists but has no reviews. Nothing on HelloPeter or Trustpilot.

  3. Business details

    6 / 15

    Email on its own domain, a phone and WhatsApp number, and a suburb (Fourways, Sandton) but no street address or company details. Domain registered on 19 January 2026.

  4. Delivery and service

    9 / 15

    Ships within South Africa in 2 to 5 working days: R120, free over R1,200. No returns policy found.

  5. Review integrity

    10 / 10

    We found no confirmed signs of fake reviews on the site.

  6. Price per mg

    4 / 10

    Best vial price is about R60 per mg (30 mg vial), against a median of R53 across the sellers we priced.

Listed prices

As shown on the seller's site on 30 September 2026. Median across the sellers we priced: about R53 per mg.

ProductPricePer mg
10 mgR950 (backorder)R95
20 mgR1,400 (out of stock)R70
30 mgR1,800R60

At a glance

Payment
PayFast
Delivery
R120, free over R1,200, 2–5 working days
Returns
No policy found
Contact
[email protected], +27 71 433 3672
Domain registered
19 January 2026
Reviews
None found

Sources

Checked 30 September 2026.

  1. ReGen-X retatrutide page
  2. SAHPRA statement on unauthorised GLP-1 products, 8 Nov 2024